… In November, the first patient was dosed in the Phase 1/2 open-label trial (PQ-110-001) to assess the safety, … six adults (≥ 18 years) who have LCA 10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. During … expertise in genetic retinal disease in the U.S. and Europe. The objectives of the trial include safety, …
… that it further strengthened its leading intellectual property estate for ADAR-mediated RNA editing by successfully defending against an opposition filed in Japan by a strawman against ProQR’s … of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) … editing levels in retinal organoid models. ProQR will develop selected genetic eye disease targets with Axiomer ® , …
… financial statements, the potential exercise of share options and the conversion of preferred shares into ordinary … period. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of … its Therapeutic Development Network, a network of CF key opinion leaders, as well as to an extensive clinical trial …